Location:
Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000
Meeting Room:
Grand Ballroom E-K (Lobby Level)
Schedule:
5:30 PM – 6:00 PM
Registration and Dinner Buffet
6:00 PM – 8:00 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.
Faculty:
Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Elizabeth O’Reilly, RN, NP, MSN, MPH
Nurse Practitioner, Breast Oncology
Susan F Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical
Trials Education
University of California, San Francisco
Medical Center
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, California
Gretchen Santos, RN, MSN, FNP-BC
University of California, San Francisco
Medical Center
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, California
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by Genentech, Lilly, Merck, Novartis and Puma Biotechnology Inc during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with early and advanced BC.
- Implement a long-term clinical plan for the management of early and advanced HER2-positive BC, incorporating existing and investigational targeted treatments.
- Recognize the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive metastatic BC (mBC).
- Develop an understanding of the frequency and potential biologic implications of PIK3CA mutations in patients with ER-positive mBC previously treated with endocrine therapy, and appreciate published research data documenting the efficacy and safety of novel agents targeting this abnormality.
- Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.
- Appreciate the biologic rationale for and available data with novel immunotherapeutic approaches to facilitate their introduction into clinical practice for appropriate patients with mBC.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements:
This educational activity for 2 contact hours is provided by RTP.
This activity is awarded 2 ANCC pharmacotherapeutic contact hours.
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.
Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.
Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
Supporters:
This activity is supported by educational grants from Genentech, Lilly, Merck, Novartis and Puma Biotechnology Inc.
Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000
Meeting Room:
Grand Ballroom E-K (Lobby Level)
The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).
Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 5 — Breast Cancer. Onsite registration will be open starting at 5:30 PM on Thursday, April 11, 2019. If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside the Grand Ballroom (Lobby Level) at the Anaheim Marriott hotel (700 West Convention Way, Anaheim, CA 92802). You may arrive up to 45 minutes before the program start time and receive a standby ticket.
If seats become available for the program, we will accept standby registration on a first come, first served basis prioritized for oncology nurses treating patients. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.